Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)

Inclusion Criteria: * Male and female subjects with a confirmed diagnosis nonsegmental vitiligo with 15% to 50% of total body surface involvement * Stable or slowly progressive vitiligo over a 3-month period * Aged 18 or more * Fitzpatrick skin types III-VI * Willing and able to comply with the conditions specified in this protocol and study procedures in the opinion of the Investigator * Providing written Informed Consent prior to the performance of any study-specific procedure. Exclusion Criteria: * Fitzpatrick skin types I-II * Vitiligo involving the hands and feet only * Extensive leukotrichia, in the opinion of the Investigator * Vitiligo of more than 5 years duration * Previous treatment with NB-UVB within 6 months prior to the Screening Visit * Patient not responsive to previous NB-UVB treatment, defined as a patient who has undergone at least 30 NB-UVB sessions with no or minimal clinically relevant pigmentary response, in the opinion of the Investigator * Allergy to afamelanotide or the polymer contained in the implant or to lignocaine/lidocaine or other local anesthetic to be used during the administration of the implant * Previous treatment with topical immunomodulators (corticosteroids, calcineurin inhibitors) for vitiligo within 4 weeks prior to the Screening Visit * History of photosensitivity disorders * Claustrophobia * History of photosensitive lupus * Any active and/or unstable autoimmune disease judged to be clinically significant by the Investigator * H…